Relapsed CLL: New Approaches Prolong Survival
Experts discuss treatment options for patients with relapsed chronic lymphocytic leukemia.
Source: medscape.com
Acerta Astrazeneca News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Acerta Astrazeneca. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Acerta Astrazeneca Today - Breaking & Trending Today
CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib
The second-generation Bruton's tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study in patients with chronic lymphocytic leukemia (CLL) .
Source: medscape.com
Zanubrutinib prolongs PFS with fewer cardiac events vs. ibrutinib in advanced CLL, SLL
NEW ORLEANS — Zanubrutinib significantly prolonged PFS compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, results of the phase 3 ALPINE study showed.The second-generation Bruton tyrosine kinase (BTK) inhibitor also had a better safety profile than ibrutinib (Imbruvica; Pharmacyclics, Janssen), particularly with
Source: healio.com